Amalgamated Bank Invests $1.04 Million in Everus (NYSE:ECG)

Amalgamated Bank bought a new position in Everus (NYSE:ECGFree Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 15,866 shares of the company’s stock, valued at approximately $1,043,000.

A number of other large investors have also bought and sold shares of ECG. Principal Securities Inc. acquired a new position in Everus in the fourth quarter worth $27,000. HighMark Wealth Management LLC bought a new position in shares of Everus in the fourth quarter valued at about $28,000. Crews Bank & Trust acquired a new position in Everus during the 4th quarter worth about $29,000. Mendota Financial Group LLC bought a new stake in Everus during the 4th quarter worth about $36,000. Finally, Blue Trust Inc. acquired a new stake in Everus in the 4th quarter valued at about $38,000.

Insider Buying and Selling

In other news, Director Rocca Michael Della bought 1,050 shares of the stock in a transaction on Tuesday, February 18th. The stock was purchased at an average price of $47.56 per share, for a total transaction of $49,938.00. Following the acquisition, the director now owns 2,027 shares in the company, valued at approximately $96,404.12. This trade represents a 107.47 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Maximillian J. Marcy acquired 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were purchased at an average price of $38.99 per share, with a total value of $50,687.00. Following the completion of the acquisition, the chief financial officer now owns 5,508 shares of the company’s stock, valued at $214,756.92. This represents a 30.89 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 3,750 shares of company stock valued at $153,853 in the last 90 days.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Stifel Nicolaus reduced their target price on shares of Everus from $85.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Wolfe Research initiated coverage on Everus in a research report on Tuesday, December 3rd. They issued a “peer perform” rating on the stock. DA Davidson started coverage on Everus in a research note on Monday, November 4th. They issued a “neutral” rating and a $55.00 target price for the company. Finally, Oppenheimer upped their price target on Everus from $70.00 to $80.00 and gave the company an “outperform” rating in a research note on Tuesday, January 7th.

View Our Latest Stock Report on ECG

Everus Price Performance

ECG opened at $39.38 on Tuesday. The business’s 50 day simple moving average is $63.22. Everus has a fifty-two week low of $37.84 and a fifty-two week high of $77.93. The company has a quick ratio of 1.50, a current ratio of 1.58 and a debt-to-equity ratio of 0.47.

Everus (NYSE:ECGGet Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The company reported $0.67 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.73 by ($0.06). Analysts forecast that Everus will post 2.49 EPS for the current year.

Everus Company Profile

(Free Report)

Everus Construction Group is providing a full spectrum of construction services through its electrical and mechanical and transmission and distribution specialty contracting services principally in United States. Its specialty contracting services are provided to utility, transportation, commercial, industrial, institutional, renewable and other customers.

Read More

Want to see what other hedge funds are holding ECG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Everus (NYSE:ECGFree Report).

Institutional Ownership by Quarter for Everus (NYSE:ECG)

Receive News & Ratings for Everus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Everus and related companies with MarketBeat.com's FREE daily email newsletter.